Quantcast
Last updated on April 24, 2014 at 13:21 EDT

Latest Glycoproteins Stories

2013-09-30 08:30:20

- GL-2045 is Gliknik's Lead Recombinant Stradomer(TM) Designed to Improve on Pooled Human Intravenous Immunoglobulin - BALTIMORE, Sept. 30, 2013 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceutical company, today announced that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for GL-2045, Gliknik's recombinant stradomer(TM), a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045...

2013-09-27 00:20:39

TOKYO, Sept. 27, 2013 /PRNewswire/ -- CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra® (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and...

2013-09-26 23:02:12

Reportbuyer.com just published a new market research report: Global Intravenous Immunoglobulin (IVIg) Industry. London (PRWEB) September 26, 2013 This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these...

2013-09-26 20:21:49

EMERYVILLE, Calif., Sept. 26, 2013 /PRNewswire/ -- Trianni, Inc., a Californian biotechnology company, announced today the launch of its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates. Monoclonal antibodies are the most successful biologic therapeutics on the market. More than thirty have been approved for use in humans and hundreds are currently undergoing testing in clinical trials for a broad range of...

2013-09-25 08:30:03

HAYWARD, Calif., Sept. 25, 2013 /PRNewswire/ -- Anthera Pharmaceuticals (NASDAQ: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that emerging data from its Phase 2b PEARL-SC study and subsequent Open-Label Extension study will be presented by Dr. Richard Furie at the 2013 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals...

2013-09-24 08:30:12

Recognized as one the most promising private biotechnology companies in the industry SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced its selection by the editors of FierceBiotech as one of the Fierce 15 for 2013. This selection designates AnaptysBio as one of the most promising private companies in the biotechnology industry, and is based upon the Company's validated antibody technology...

2013-09-24 04:22:08

Breakthrough Inovio DNA Technology Application Successfully Demonstrates Monoclonal Antibody Generation BLUE BELL, Pa., Sept. 24, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today the publication of a peer-reviewed paper demonstrating the success of its new DNA plasmid technology in generating therapeutic monoclonal antibodies. In this study in mice, a prototype monoclonal antibody construct encoding for an established anti-HIV monoclonal antibody...

2013-09-12 04:22:30

BREDA, the Netherlands and GHENT, Belgium, September 12, 2013 /PRNewswire/ -- - Breakthrough data to be presented during the 'Discovery on Target' conference in Boston, MA, USA on September 23, 2013 arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody(TM) technology. Nav1.7 has been thoroughly validated...

2013-09-10 08:30:54

Full Spectrum Genetics CEO Joins AvidBiotics Scientific Advisory Board SOUTH SAN FRANCISCO, Calif., Sept. 10, 2013 /PRNewswire/ -- AvidBiotics today announced a research collaboration with Full Spectrum Genetics for the purpose of optimizing multiple therapeutic protein candidates from AvidBiotics' Micacide(TM) protein immuno-oncology and antiviral platform. AvidBiotics also announced that Bob DuBridge, Ph.D., Chief Executive Officer of Full Spectrum Genetics, has joined the...

2013-08-28 08:25:52

JERUSALEM, Aug. 28, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its abstract entitled "BL-7010: Non-Absorbable Polymeric Sequestering Agent for Celiac Disease" was accepted for an oral presentation at the 15th International Celiac Disease Symposium, which will take place September 22-25, 2013 in Chicago. Yotam Nisemblat, Senior Drug Development Manager at BioLineRx, will present BL-7010 for the treatment of...